SecBot SecBot
8-K ·Filed Mar 31, 2026

INKT

MiNK Therapeutics, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago SEC0001193125-26-133346
earnings-rerun-backfill
Actionable Insight ▲ Bullish

Monitor for Phase 2 trial initiations in ARDS and GVHD in 1H 2026, with early data expected by year-end. The non-dilutive funding and cash runway through 2026 reduce near-term financing risk, making clinical readouts the key value drivers.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.53
T+0 close · Mar 31, 2026 · via day close
Latest settled
+10.54%
T+60 · $11.64
Vs SPY
−1.84%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 31 $10.53entry
  2. T+1 · 8mo ago +0.38%α −0.37% · $10.57
  3. T+5 · 7mo ago +5.89%α +1.94% · $11.15
  4. T+20 · 7mo ago +4.61%α −4.82% · $11.02
  5. T+60 · 5mo ago +10.54%α −1.84% · $11.64
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

MiNK Therapeutics reported Q4 2025 financial results showing a narrower-than-expected net loss of $0.56 per share (beat vs $0.68 consensus), driven by non-dilutive funding and advancing clinical programs. Key catalysts include Phase 2 trials for ARDS/hypoxemic pneumonia (initiation in 1H 2026, data by year-end) and graft-versus-host disease (first dosing expected May 2026), supported by NIH and philanthropic grants. The company ended 2025 with $13.4M cash, extended to 2026 via $3M raised from its ATM program.

Key Financial Metrics

EPS
−$0.56
est −$0.68 · +17.6%
Revenue
$0.00
est $0.00 · 0.0%
Rating
beat

Key Facts

  • Q4 2025 net loss of $2.6M ($0.56/share), beating consensus of $0.68/share.
  • Phase 2 trial for ARDS/hypoxemic pneumonia to initiate in 1H 2026, with early data expected by year-end.
  • GVHD program fully funded by NIH STTR grant and Mary Gooze award; first patient dosing expected May 2026.
  • Ended 2025 with $13.4M cash; raised $3M since year-end via ATM, providing runway through 2026.
  • Appointed Melissa Orilall as Principal Financial Officer and Col. (Ret.) John Holcomb to the Board.

Financial Impact

Net loss of $2.6M ($0.56/share) for Q4 2025, beating consensus by $0.12/share.

epscashnetLoss

Risk Factors

  • High cash burn typical of early-stage biotech; future dilution possible if additional funding is needed.
  • Clinical trial delays or negative data could significantly impact stock price.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-133346
Document: inkt-ex99_1.htm0001193125-26-133346
Document: 0001193125-26-133346-index-headers.html0001193125-26-133346
Document: 0001193125-26-133346-index.html0001193125-26-133346
Document: 0001193125-26-133346.txt0001193125-26-133346
8-K Data (Synthetic)0001193125-26-133346

Track record

21 reports on INKT

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
  3. Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
  4. Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
  5. Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
  6. Aug 13, 202613w ago 8-K Mixed 6/10 No price data
  7. Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
  8. Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
  9. May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
  10. May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 8h 10m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026